Skip to content

Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy

Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy - a Cross-sectional Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07346521
Acronym
G-SCOGE
Enrollment
1000
Registered
2026-01-16
Start date
2025-12-16
Completion date
2026-12-16
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barett's Esophagus, HELICOBACTER PYLORI INFECTIONS, Intestinal Metaplasia

Brief summary

The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy. Endoscopic screening of the stomach is yet not acceptet as a standard screening procedure in Western countries. However, Helicobacter pylori infection is known to increase the risk of developing gastric cancer. This study will look at the prevalence of Helicobacter pylori infection in asymptomatic patients who have an additional gastroscopy during the same session as their screening colonoscopy. It will also record other early tissue changes or risk factors for stomach cancer, such as intestinal metaplasia and Barrett's mucosa. The main questions this study aims to answer are: * How often is Helicobacter pylori found in adults without upper gastrointestinal symptoms by use of OGD? * Are there any correlations between H. pylori infection and other risk factors, such as BMI, smoking, alcohol consumption, or a family history of colorectal and/or stomach cancer? About 1000 participants are expected to take part. Adults undergoing a screening colonoscopy at a private endoscopy center will be offered the chance to have an additional gastroscopy if they meet the study's inclusion criteria (no previous Helicobacter pylori infection and no upper gastrointestinal symptoms). Small tissue samples (biopsies) will be taken from the stomach and lower esophagus during the gastroscopy. Biopsies will be checked histologically for the presence of Helicobacter pylori and early tissue changes. During the gastroscopy, no additional procedures or biopsies will be done beyond what is normally performed during a routine examination. Everything done during this procedure follows the standard steps of a regular gastroscopy. All data will be coded to protect participant privacy. Researchers will use statistical methods to find out how common Helicobacter pylori infection is and whether it is related to other lifestyle or family risk factors or tissue changes.

Interventions

None listed

Sponsors

Sigmund Freud PrivatUniversitat
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 30 years * Scheduled screening colonoscopy (either initial screening or surveillance following previously detected polyps) * Asymptomatic (no gastrointestinal symptoms) * Willingness and consent to undergo simultaneous gastroscopy with biopsy sampling * Written informed consent to participate in the study, including the use of histological findings and patient data for study analysis

Exclusion criteria

* Known Helicobacter pylori infection or previous treatment for H. pylori * Current or recent proton pump inhibitor (PPI) therapy (\< 4 weeks) * Pre-existing gastrointestinal diseases (e.g., chronic gastritis, ulcer, gastric carcinoma) * Immunosuppression or relevant underlying diseases * Refusal to undergo additional gastroscopy or biopsy

Design outcomes

Primary

MeasureTime frameDescription
The number of asymptomatic patients who are Helicobacter-positive.From enrollment to the end of observation at 7 daysAll study participants undergo upper gastrointestinal endoscopy (gastroscopy). During the procedure, gastric biopsy specimens are obtained and subsequently processed for histopathological evaluation. The biopsies are analyzed to determine the presence of Helicobacter pylori infection. For statistical analysis, Helicobacter pylori status is coded as follows: absence of infection is recorded as 0, mild infection as 1, moderate infection as 2, and severe infection as 3.

Secondary

MeasureTime frameDescription
Asymptomatic patients who exhibit intestinal metaplasia and/or Barrett's mucosa.From enrollment to the end of observation at 7 daysDuring gastroscopy, biopsy specimens are obtained according to standard endoscopic protocols. Gastric biopsies are histopathologically processed and evaluated for the presence of intestinal metaplasia and Barrett's esophagus. Biopsies obtained from the stomach (Sydney Biopsie Protocol) the ora serrata are likewise histologically examined to identify the presence of Barrett's esophagus and/or intestinal metaplasia.The overall objective of this analysis is to assess the correlation, as well as the strength of the association, between the primary outcome, Helicobacter pylori infection, and the secondary outcomes, namely intestinal metaplasia and Barrett's mucosa.

Countries

Austria

Contacts

CONTACTHarald Rosen, Univ. Prof. Dr.
rosensurg@csi.com+43 664 4422571

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026